Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA4 | P22748 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.32 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10453882 | 1.00 | KMT2A (0.52) | KMT2ACA1CA2CA4HTT | |
| SCHEMBL20610546 | 0.98 | CA1 (0.50) | KMT2ACA1CA2CA4HTT | |
| SCHEMBL30492691 | 0.98 | CA1 (0.50) | KMT2ACA1CA2CA4HTT | |
| SCHEMBL873373 | 0.98 | CA1 (0.50) | KMT2ACA1CA2CA4HTT | |
| Hydroxyamine SCHEMBL10747806 | 0.91 | CA1 (0.45) | KMT2ACA1CA2CA4HTT | |
| SCHEMBL2690457 | 0.91 | CA1 (0.41) | KMT2ACA1CA2CA4NPC1 | |
| SCHEMBL7871587 | 0.84 | CA1 (0.50) | KMT2ACA1CA2CA4HTT | |
| SCHEMBL11729637 | 0.83 | KMT2A (0.48) | KMT2ACA1CA2CA4HTT | |
| SCHEMBL11831131 | 0.81 | CA1 (0.39) | KMT2ACA1CA2CA4NPC1 | |
| SCHEMBL2689978 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731967-B2 | Inhibitors of TRIM33 and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731967-B2 | Inhibitors of TRIM33 and methods of use | TRIM33, TRIM28, TRIM4 | KMT2A 1335/4885CA1 4391/4885CA2 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.